Portopulmonary hypertension -: Survival and prognostic factors

被引:167
作者
Le Pavec, Jerome [1 ]
Souza, Rogerio [1 ]
Herve, Philippe [1 ]
Lebrec, Didier [2 ,3 ]
Savale, Laurent [1 ]
Tcherakian, Colas [1 ]
Jais, Xavier [1 ]
Yaici, Azzedine [1 ]
Humbert, Marc [1 ]
Simonneau, Gerald [1 ]
Sitbon, Olivier [1 ]
机构
[1] Univ Paris 11, Hop Antoine Beclere, AP HP, Serv Pneumol & Reanimat,UPRES 2705, Clamart, France
[2] Hop Beaujon, INSERM, U773, Ctr Rech Biomed Bichat Beaujon,CRB3,AP HP, Clichy, France
[3] Hop Beaujon, AP HP, Serv Hepatol, Clichy, France
关键词
pulmonary hypertension; portal hypertension; portopulmonary hypertension; cirrhosis; survival;
D O I
10.1164/rccm.200804-613OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Portopulmonary hypertension (PoPH) can be defined as elevation of pulmonary arterial pressure and pulmonary vascular resistance in the setting of portal hypertension. Survival results in PoPH are contrasting, and prognostic factors need to be identified. Objectives: To analyze long-term survival in a large cohort of patients with PoPH with the aim of determining the independent variables affecting survival. Methods: We retrospectively analyzed charts of all patients referred to the French Referral Center for pulmonary arterial hypertension with the diagnosis of PoPH between 1984 and 2004. Measurements and Main Results: The study population comprised 154 patients; 57% male. Mean age at diagnosis was 49 +/- 11 years, 60%of patients were in New York Heart Association functional class III-IV, and mean 6-minute walk distance was 326 +/- 116 m. Hemodynamic measurements showed a mean pulmonary arterial pressure of 53 +/- 13 mm Hg, cardiac index of 2.9 0.9 L/min/m(2), and pulmonary vascular resistance of 752 +/- 377 dyn/s/cm(5). Portal hypertension was related to cirrhosis in 136 patients, with a severity assessed as follows: Child-Pugh class A 51%, Child-Pugh class B 38%, Child-Pugh class C 11%. Overall survival rates at 1, 3, and 5 yr were 88, 75, and 68%, respectively. Multivariate regression analysis individualized the presence and severity of cirrhosis and cardiac index as major independent prognostic factors. Conclusions: Prognosis in PoPH is mainly related to the presence and severity of cirrhosis and to cardiac function. The place of pulmonary arterial hypertension-specific therapies remains to be determined in the setting of PoPH.
引用
收藏
页码:637 / 643
页数:7
相关论文
共 35 条
  • [1] The impact of treatment of portopulmonary hypertension on survival following liver transplantation
    Ashfaq, M.
    Chinnakotla, S.
    Rogers, L.
    Ausloos, K.
    Saadeh, S.
    Klintmalm, G. B.
    Ramsay, M.
    Davis, G. L.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (05) : 1258 - 1264
  • [2] BENHAMOU JP, 1999, MALADIES FOIE VOIES
  • [3] Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients
    Castro, M
    Krowka, MJ
    Schroeder, DR
    Beck, KC
    Plevak, DJ
    Rettke, SR
    Cortese, DA
    Wiesner, RH
    [J]. MAYO CLINIC PROCEEDINGS, 1996, 71 (06) : 543 - 551
  • [4] Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study
    Colle, IO
    Moreau, R
    Godinho, E
    Belghiti, J
    Ettori, F
    Cohen-Solal, A
    Mal, H
    Bernuau, J
    Marty, J
    Lebrec, D
    Valla, D
    Durand, F
    [J]. HEPATOLOGY, 2003, 37 (02) : 401 - 409
  • [5] Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
    D'Amico, G
    Garcia-Tsao, G
    Pagliaro, L
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (01) : 217 - 231
  • [6] Mechanisms of disease: Pulmonary arterial hypertension
    Farber, HW
    Loscalzo, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (16) : 1655 - 1665
  • [7] Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension
    Findlay, JY
    Plevak, DJ
    Krowka, MJ
    Sack, EM
    Porayko, MK
    [J]. LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (05): : 362 - 365
  • [8] Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension:: With pulmonary arterial hypertension:: A randomized, double-blind, placebo-controlled trial
    Galiè, N
    Humbert, M
    Vachiéry, JL
    Vizza, CD
    Kneussl, M
    Manes, A
    Sitbon, O
    Torbicki, A
    Delcroix, M
    Naeije, R
    Hoeper, M
    Chaouat, A
    Morand, S
    Besse, B
    Simonneau, G
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (09) : 1496 - 1502
  • [9] Guidelines on diagnosis and treatment of pulmonary arterial hypertension -: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
    Galiè, N
    Torbicki, A
    Barst, R
    Dartevelle, P
    Haworth, S
    Higenbottam, T
    Olschewski, H
    Peacock, A
    Pietra, G
    Rubin, LJ
    Simonneau, G
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 (24) : 2243 - 2278
  • [10] Portopulmonary hypertension
    Golbin, Jason M.
    Krowka, Michael J.
    [J]. CLINICS IN CHEST MEDICINE, 2007, 28 (01) : 203 - +